EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share (EDAP)
4.3200
+0.00 (0.00%)
NASDAQ· Last Trade: Jun 1st, 10:56 PM EDT
Detailed Quote
Previous Close
4.320
Open
-
Bid
4.340
Ask
4.540
Day's Range
N/A - N/A
52 Week Range
1.210 - 5.050
Volume
0
Market Cap
160.29M
PE Ratio (TTM)
-8.471
EPS (TTM)
-0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
41,392
Chart
About EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share (EDAP)
Edap Tms Sa is a biomedical company specializing in the development and commercialization of innovative medical devices and treatment solutions for urological diseases. The firm focuses on providing advanced technologies for the management of kidney stones, prostate cancer, and benign prostatic hyperplasia. Its offerings include lithotripsy systems, which utilize ultrasound to break down kidney stones, as well as software and robotic solutions aimed at enhancing surgical precision and patient outcomes. Through its dedication to research and development, Edap aims to improve the quality of care in the urology field while promoting minimally invasive procedures for patients. Read More
Edap Tms (NASDAQ:EDAP) used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company’s Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and futur
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix’s commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP’s Focal One Robotic HIFU and Telix’s PSMA PET imaging products in the management of prostate cancer.
